Kinnate Biopharma has filed a patent for inhibitors of receptor tyrosine kinase effector, RAF, along with pharmaceutical compositions containing these compounds. The patent aims to use these compounds for the treatment of diseases. GlobalData’s report on Kinnate Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Kinnate Biopharma Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Kinnate Biopharma, targeted cancer therapy was a key innovation area identified from patents. Kinnate Biopharma's grant share as of September 2023 was 11%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20230303566A1) describes a compound and its pharmaceutically acceptable forms. The compound has a specific structure, as represented by Formula (Ia). The structure includes various substituents and functional groups, denoted by X, Y, Z, R1, R2, R3, and W. These substituents can be independently selected from a range of options, including hydrogen, halogen, alkyl, cycloalkyl, and heterocyclyl groups.

The patent claims specify different variations of the compound based on the substituents. For example, claim 4 states that the compound can have X as C-R1, claim 5 specifies Y as N and Z as N, claim 6 states Y as C-R2 and Z as N, and claim 7 states Y as N and Z as C-R3. Similar variations are mentioned in subsequent claims.

The patent also mentions the possibility of different substituents for R2 and R3. Claim 33 specifies R2 as H, claim 34 states R2 as halogen, claim 36 mentions R2 as optionally substituted alkyl, and claim 37 mentions R2 as optionally substituted cycloalkyl. Similarly, claim 39 specifies R3 as H, claim 40 states R3 as halogen, and claim 41 mentions R3 as fluorine.

The patent further describes the compound's structure with respect to the substituent W. Claim 51 states that W can be an optionally substituted nitrogen-containing heteroaryl. Specific examples of W include pyrazyl, imidazyl, triazyl, tetrazyl, oxaz-2-yl, oxaz-4-yl, and oxaz-5-yl.

The patent also includes a claim for a pharmaceutical composition comprising the compound described in claim 2 and a pharmaceutically acceptable excipient.

Overall, the patent describes a compound and its various variations, including different substituents and functional groups. The compound and its pharmaceutically acceptable forms have potential applications in the field of pharmaceuticals.

To know more about GlobalData’s detailed insights on Kinnate Biopharma, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies